US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Johnson & Johnson

JNJNYSE

181.40

USD
+1.96
(+1.09%)
After Hours Market
24.13P/E
17Forward P/E
0.93P/E to S&P500
477.336BMarket CAP
2.36%Div Yield

Johnson & Johnson

NYSE:JNJ

RECENT
PRICE

181.40

P/E
RATIO

24.13

(PEG:0.58)

P/E RATIO
RELATIVE
TO S&P

0.93

DIV
YLD

2.51%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.72 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2010

2011

2012

2012

2013

2014

2016

2017

2017

2018

2019

2021

2022

TTM

Fiscal year

18.14

3.76

3.92

1.45

21.20

3.67

4.14

1.62

22.67

4.61

4.23

1.79

22.43

4.44

5.15

1.93

22.49

4.87

5.11

2.12

23.87

3.55

4.19

2.26

24.19

3.91

4.49

2.38

25.28

4.90

4.90

2.58

26.71

5.86

5.30

2.79

25.43

5.59

5.74

2.97

26.56

6.11

5.74

3.19

28.50

0.48

6.63

3.33

30.64

5.75

6.96

3.57

31.17

5.74

7.57

3.77

31.37

5.59

7.67

3.98

35.63

7.93

7.51

4.19

36.07

7.53

7.50

4.24

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.93

13.38

1.15

15.03

1.09

15.12

0.86

18.33

0.87

20.66

1.06

20.95

1.06

23.33

1.27

26.25

1.33

25.06

1.26

25.82

1.19

26.02

1.22

22.43

1.38

22.44

1.33

22.59

1.27

24.04

1.39

28.12

1.36

27.42

CAPEX per share

Book Value per share

2,940

2,882

2,812

2,760

2,738

2,724

2,778

2,821

2,783

2,755

2,707

2,683

2,662

2,633

2,633

2,632

2,631

Comm.Shares outs.(m)

16.5

0.9

2.3%

17.4

1.0

2.5%

14.0

0.7

2.8%

13.9

0.7

3.1%

13.0

0.8

3.3%

18.9

1.3

3.4%

17.2

1.2

3.6%

17.4

1.0

3.0%

17.1

0.9

2.8%

20.3

0.9

2.6%

21.2

0.9

2.5%

267.4

11.3

2.6%

23.1

0.9

2.7%

23.5

1.0

2.8%

29.6

1.0

2.4%

21.7

0.8

2.4%

24.1

0.9

2.5%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (3/4/22 | Q1)

Total liabilities
$103,646 m.

Total assets
$178,355 m.

Long-term debt
$28,851 m.

Cash and equiv.
$10,463 m.

Goodwill $34,935 m.

Retained earnings $124,380 m.

Common stock 2,630 m. shares

Market Capitalisation
$471,231 m. (as of 24/5/22)

65,030

24.8%

67,224

25.3%

71,312

26.6%

74,331

28.4%

70,074

26.1%

71,890

29.4%

76,450

25.0%

81,581

26.0%

82,059

25.6%

82,584

24.1%

93,775

26.2%

94,880

25.7%

Revenue (m)

Operating margin

3,158

9,672

3,666

10,853

4,104

13,831

3,895

16,323

3,746

15,409

3,754

16,540

5,642

1,300

6,929

15,297

7,009

15,119

7,231

14,714

7,390

20,878

5,496

19,830

Depreciation (m)

Net profit (m)

21.8%

14.9%

23.7%

16.1%

10.6%

19.4%

20.6%

22.0%

19.7%

22.0%

16.5%

23.0%

92.6%

1.7%

15.0%

18.8%

12.7%

18.4%

10.8%

17.8%

8.3%

22.3%

6.2%

20.9%

Income tax rate

Net profit margin

31,505

12,969

57,080

21,854

11,489

64,826

30,732

13,328

74,053

34,226

15,122

69,752

32,463

12,857

71,150

38,745

22,442

70,418

12,551

30,675

60,160

14,803

27,684

59,752

9,310

26,494

59,471

8,744

32,635

63,278

15,753

29,985

74,023

17,034

28,851

74,709

Working capital (m)

Long-term debt (m)

Equity (m)

11.1%

11.4%

16.9%

11.5%

12.1%

16.7%

13.3%

12.0%

18.7%

15.8%

16.1%

23.4%

15.0%

14.8%

21.7%

14.9%

14.5%

23.5%

1.1%

11.8%

2.2%

13.3%

12.4%

25.6%

12.6%

11.2%

25.4%

11.2%

9.5%

23.3%

15.4%

12.6%

28.2%

14.8%

12.0%

26.5%

ROIC

Return on capital

Return on equity

Working Capital

2019

2021

2022

Cash assets

19,287

27,771

28,273

Receivables

14,481

13,576

15,283

Inventory

9,020

9,344

10,387

Other

2,486

3,132

3,701

Current assets

45,274

51,237

60,979

Acc. Payable

8,544

9,505

11,055

Debt due

1,202

2,631

3,766

Other

26,218

30,357

30,405

Current liab.

35,964

42,493

45,226

36.4%

76.1%

39.1%

156.7%

47.3%

78.3%

52.4%

100.9%

47.0%

85.1%

47.9%

113.2%

(587.9)%

86.1%

37.9%

82.9%

34.4%

83.7%

28.8%

67.9%

47.2%

73.3%

43.7%

74.8%

Plowback ratio

Div.&Repurch. to FCF

Johnson & Johnson (US) started trading on September 1, 1944 (cik: 0000200406), operates in the Healthcare sector (Drug Manufacturers—General industry), has 144,000 full-time employees, and is led by Mr. Alex Gorsky. Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and healthcare professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

5.37%

3.89%

Cash flow

2.74%

5.38%

Earnings

278.69%

118.87%

Dividends

5.39%

5.86%

Book value

5.56%

1.90%

Insider trading

Type

Shares

Date

Hait William

Exempt

29,699

04/21/22

Hait William

Sale

22,591

04/21/22

Hait William

Sale

2,884

04/21/22

Hait William

Sale

1,696

04/21/22

Hait William

Sale

1,403

04/21/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2021

20,691

18,336

21,082

22,475

82,584

2022

22,321

23,312

23,338

24,804

93,775

2023

23,426

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2021

2.20

1.38

1.35

0.66

5.59

2022

2.35

2.39

1.39

1.80

7.93

2023

1.96

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2021

0.95

1.01

1.01

1.01

3.98

2022

1.01

1.06

1.06

1.06

4.19

2023

1.06

- -

- -

- -

- -

05/11/2022

J&J Names Executives of Tylenol, Band-Aid Company

The Wall Street Journal - Read more...

05/05/2022

FDA Limits Use of Johnson & Johnson’s Covid-19 Vaccine

The Wall Street Journal - Read more...

05/04/2022

J&J Sues Drug-Benefit Middleman Over Drug-Cost Assistance Program

The Wall Street Journal - Read more...

04/26/2022

Johnson & Johnson Sues Alleged HIV-Drug Counterfeiters

The Wall Street Journal - Read more...

04/19/2022

Johnson & Johnson Backs Off Covid Vaccine Sales Guidance

The Wall Street Journal - Read more...

04/18/2022

J&J Settles With West Virginia in Opioid Suit for $99 Million

The Wall Street Journal - Read more...

03/30/2022

Justice Department Probes Alleged Sales of Counterfeit HIV Drugs

The Wall Street Journal - Read more...

02/28/2022

FDA Approves Cell-Based Therapy for Blood Cancer Discovered in China

The Wall Street Journal - Read more...

02/25/2022

Johnson & Johnson, Drug Distributors Agree to Opioid Settlement With States

The Wall Street Journal - Read more...

02/25/2022

Judge Backs J&J’s Talc Bankruptcy, Keeping Cancer Lawsuits Frozen

The Wall Street Journal - Read more...

02/02/2022

Native American Tribes Reach $590 Million Opioid Settlement

The Wall Street Journal - Read more...

01/25/2022

Johnson & Johnson Posts Higher Quarterly Sales Despite Some Pandemic-Related Pains

The Wall Street Journal - Read more...

01/25/2022

AMC, IBM, Microsoft, GE: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/17/2021

Rivian, FedEx, Cerner, Oracle: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/17/2021

CDC Recommends Pfizer, Moderna Covid-19 Vaccines Over J&J’s

The Wall Street Journal - Read more...

12/06/2021

J&J Prepares to Untangle Finances Ahead of Planned Split

The Wall Street Journal - Read more...

11/29/2021

Omicron Variant Has Covid-19 Vaccine Makers Preparing for Worst Case

The Wall Street Journal - Read more...

11/29/2021

Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/26/2021

J&J Covid-19 Vaccine Recipients Shift to Other Boosters

The Wall Street Journal - Read more...

11/21/2021

Most Vulnerable More at Risk of Breakthrough Hospitalization

The Wall Street Journal - Read more...

11/12/2021

What to Know About Johnson & Johnson’s Breakup

The Wall Street Journal - Read more...

11/12/2021

Johnson & Johnson Breakup Is No Clean Sweep

The Wall Street Journal - Read more...

11/12/2021

Johnson & Johnson to Split Consumer From Pharmaceutical, Medical-Device Businesses, Creating Two Companies

The Wall Street Journal - Read more...

11/12/2021

Rivian Automotive Stock Price: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/12/2021

J&J Split Sees Band-Aid, Tylenol Go Their Own Way

The Wall Street Journal - Read more...

11/12/2021

How Bankruptcy Could Help Johnson & Johnson Corral Vast Talc Litigation

The Wall Street Journal - Read more...

11/11/2021

J&J Talc Bankruptcy Case Moved to New Jersey From North Carolina

The Wall Street Journal - Read more...

11/09/2021

Johnson & Johnson Opioid Verdict Overturned by Oklahoma Supreme Court

The Wall Street Journal - Read more...

11/03/2021

Vaccine Boosters’ Mix-and-Match Efficacy

The Wall Street Journal - Read more...

11/02/2021

Opioid Manufacturers Score Win in California Lawsuit

The Wall Street Journal - Read more...

10/22/2021

Moderna and J&J Covid-19 Booster Shots Backed by CDC

The Wall Street Journal - Read more...

10/20/2021

FDA Authorizes Covid-19 Vaccine Boosters From Moderna, J&J

The Wall Street Journal - Read more...

10/19/2021

Johnson & Johnson’s Sales Climb Across Divisions

The Wall Street Journal - Read more...

10/19/2021

Johnson & Johnson’s Stock Deserves a Booster

The Wall Street Journal - Read more...

10/19/2021

Dover, Procter & Gamble, Travelers, Netflix: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/18/2021

FDA Nears Approval for Mixing Covid-19 Booster Shots

The Wall Street Journal - Read more...

10/18/2021

Zillow, State Street, Valneva, Upstart: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/15/2021

J&J Covid-19 Booster Shot Endorsed by FDA Advisers

The Wall Street Journal - Read more...

10/13/2021

J&J Booster Dose Bolsters Protection Against Covid-19, FDA Says

The Wall Street Journal - Read more...

10/12/2021

Johnson & Johnson’s Top Scientist to Depart

The Wall Street Journal - Read more...

10/05/2021

Johnson & Johnson Asks FDA to Authorize Covid-19 Booster

The Wall Street Journal - Read more...

09/17/2021

Moderna’s Covid-19 Shot Best Prevents Hospitalization, Study Indicates

The Wall Street Journal - Read more...

09/04/2021

Covid-19 Vaccine Booster Launch Could Be Delayed for Many

The Wall Street Journal - Read more...

08/31/2021

Zoom Video, AMC, CrowdStrike: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

08/28/2021

Covid-19 Vaccine Efficacy: What Do the Numbers Really Mean?

The Wall Street Journal - Read more...

08/25/2021

J&J Says Covid-19 Booster Prompts Strong Immune Response

The Wall Street Journal - Read more...

08/17/2021

As Delta Surges, Covid-19 Breakthrough Cases Remain Uncommon

The Wall Street Journal - Read more...

08/12/2021

Vaccine Scammers Target Authorities in Dozens of Countries

The Wall Street Journal - Read more...

08/12/2021

FDA Moving Toward Decision Authorizing Booster Shot for Immunocompromised

The Wall Street Journal - Read more...

08/06/2021

J&J Vaccine Highly Effective Against Delta Variant in South African Trial

The Wall Street Journal - Read more...

08/03/2021

U.S. Has Shared 110 Million Covid-19 Vaccine Doses Overseas

The Wall Street Journal - Read more...

07/29/2021

J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Plant

The Wall Street Journal - Read more...

07/21/2021

Johnson & Johnson Posts Higher Quarterly Profit

The Wall Street Journal - Read more...

07/21/2021

Coca-Cola, Johnson & Johnson, Chipotle: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

07/20/2021

$26 Billion Opioid Settlement Expected This Week

The Wall Street Journal - Read more...

07/15/2021

Blackstone, AIG, NortonLifeLock, Morgan Stanley: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

07/12/2021

FDA Warns J&J Covid-19 Vaccine Raises Risk of Rare Neurological Condition

The Wall Street Journal - Read more...

07/02/2021

J&J Vaccine Shows Promise Protecting Against Delta Variant

The Wall Street Journal - Read more...

06/26/2021

Johnson & Johnson Settles New York Opioid Case for $230 Million

The Wall Street Journal - Read more...

06/16/2021

Roblox, Oracle, Greenland Tech, Kindred Biosciences: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

06/11/2021

FDA Approves Export of Covid-19 Vaccine Doses From Troubled Plant

The Wall Street Journal - Read more...

06/08/2021

Millions of J&J Covid-19 Vaccines Are at Risk of Expiring in June

The Wall Street Journal - Read more...

06/01/2021

Supreme Court Won’t Consider Johnson & Johnson Challenge to Baby Powder Judgment

The Wall Street Journal - Read more...

05/28/2021

FDA, J&J Near Deal for Vaccine Production at Baltimore Plant

The Wall Street Journal - Read more...

05/09/2021

J&J Vaccine Pause Stoked Hesitancy That Threatens Covid-19 Vaccination Drive

The Wall Street Journal - Read more...

05/07/2021

AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emergency-Use Application

The Wall Street Journal - Read more...

05/06/2021

U.S. Backs Waiver of Intellectual Property Protection for Covid-19 Vaccines

The Wall Street Journal - Read more...

05/02/2021

Opioid-Crisis Lawsuit Heads for Trial in West Virginia

The Wall Street Journal - Read more...

04/26/2021

W.R. Grace, AMC, Ocugen, Carnival: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

04/25/2021

Vaccination Sites Restart J&J’s Covid-19 Vaccinations

The Wall Street Journal - Read more...

04/24/2021

U.S. Lifts Pause on J&J’s Covid Vaccine

The Wall Street Journal - Read more...

04/24/2021

Do J&J and AstraZeneca Vaccines Cause Blood Clots, and What Are the Symptoms?

The Wall Street Journal - Read more...

04/21/2021

FDA Finds Poor Conditions at Contractor’s Plant Making J&J Vaccine

The Wall Street Journal - Read more...

04/20/2021

J&J Vaccine Benefits Outweigh Risks, EU Agency Says, as U.S. Cases Rise

The Wall Street Journal - Read more...

04/20/2021

J&J’s Covid-19 Vaccine Adds $100 Million to Quarterly Sales

The Wall Street Journal - Read more...

04/20/2021

Kansas City Southern, IBM, United Airlines: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

04/18/2021

J&J Vaccine Pause Driven by Risk of Mistreating Clots

The Wall Street Journal - Read more...

04/18/2021

Fauci Predicts J&J Vaccine Returning Friday, Perhaps With Limits, Warnings

The Wall Street Journal - Read more...

04/16/2021

J&J Privately Asked Rival Vaccine Makers to Probe Clot Risks

The Wall Street Journal - Read more...

04/14/2021

U.S. Vaccine Panel Delays Vote on J&J Covid-19 Shot’s Clot Risk

The Wall Street Journal - Read more...

04/13/2021

Covid-19 Vaccine Issues Present New Challenge for J&J

The Wall Street Journal - Read more...

04/13/2021

J&J Vaccine Clot Issue Shows Limits of Clinical Trials, Scientists Say

The Wall Street Journal - Read more...

04/13/2021

J&J’s Covid-19 One-Shot Vaccine: What You Need to Know

The Wall Street Journal - Read more...